Research map: Reframing MASLD: A Hepatic Condition with Systemic Clinical Impact

Back to the article

Papers in this map

  1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 · Theo Vos · 2020 · 20004 citations · Cited by this paper
  2. Integrating Cardiovascular Risk Assessment into MASLD Drug Development · Ahmad Alam · 2026 · Cites this paper
  3. Molecular Biomarkers and Risk Prediction Models for Acute Kidney Injury Following Liver Transplantation: A Review · 2026 · Related
  4. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes · Zobair M. Younossi · 2015 · 11046 citations · Cited by this paper
  5. Long-term Outcomes of Percutaneous Biodegradable Stent Placement for Hepaticojejunostomy Strictures · 2026 · Related
  6. Nonalcoholic Fatty Liver Disease · Paul G. Angulo · 2002 · 5215 citations · Cited by this paper
  7. Candesartan Cilexetil Restores Renal Endothelial Function Through Modulation of the ADMA–DDAH–eNOS Pathway in Experimental ACLF-Associated Renal Dysfunction · 2026 · Related
  8. Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension · Paul E. Peppard · 2000 · 5003 citations · Cited by this paper
  9. Overlap Syndromes and Associated Immunoglobulin-G4-Related Liver Diseases · 2026 · Related
  10. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement · Mohammed Eslam · 2020 · 4543 citations · Cited by this paper
  11. Recurrent Liver Failure due to SCYL1 Deficiency: A Report of 2 Cases and a Review of the Literature · 2026 · Related
  12. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease · Kerry L. Donnelly · 2005 · 3539 citations · Cited by this paper
  13. Assessment of Liver Volumes Using Semiautomated Segmentation and Development of a Predictive Formula in the Indian Population · 2026 · Related
  14. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease · Paul G. Angulo · 2015 · 3025 citations · Cited by this paper
  15. Acute Kidney Injury After Acute Viral Hepatitis A in Adults: Incidence, Predictors, and Impact on Outcomes · 2026 · Related
  16. Diabetic Kidney Disease · Radica Z. Alicic · 2017 · 2909 citations · Cited by this paper
  17. Inflammatory Myofibroblastic Tumour of the Liver: Experience From a Specialised Paediatric Liver Centre · 2026 · Related
  18. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease · Mary Eugenia Rinella · 2023 · 2555 citations · Cited by this paper
  19. Methodological considerations in the interpretation of non-invasive surrogate markers in a post hoc analysis of pemafibrate in MASLD · 2026 · Related
  20. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease · Chris Estes · 2017 · 2456 citations · Cited by this paper
  21. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries · 2018 · Related
  22. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis · April Wang Armstrong · 2020 · 2351 citations · Cited by this paper
  23. Mitochondrial Dysfunction and Type 2 Diabetes · Bradford B. Lowell · 2005 · 2077 citations · Cited by this paper
  24. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease · Giovanni Targher · 2010 · 1928 citations · Cited by this paper
  25. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease · Laurent Castéra · 2019 · 1518 citations · Cited by this paper
  26. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis · Giovanni Targher · 2016 · 1458 citations · Cited by this paper
  27. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes · Federica Zatterale · 2020 · 1178 citations · Cited by this paper
  28. Psoriasis and comorbid diseases · Junko Takeshita · 2017 · 1164 citations · Cited by this paper
  29. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease · Mark J. Sarnak · 2003 · 1157 citations · Cited by this paper
  30. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD · Hannes Hagström · 2017 · 1099 citations · Cited by this paper
  31. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus · Kenneth J. Cusi · 2016 · 1018 citations · Cited by this paper
  32. The interaction of hepatic lipid and glucose metabolism in liver diseases · Lars P. Bechmann · 2011 · 1013 citations · Cited by this paper
  33. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis · Arun J. Sanyal · 2025 · 985 citations · Cited by this paper
  34. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation · Tamás Varga · 2011 · 932 citations · Cited by this paper
  35. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 · Ralph A. DeFronzo · 2010 · 898 citations · Cited by this paper
  36. Epidemiology of metabolic dysfunction-associated steatotic liver disease · Zobair M. Younossi · 2024 · 876 citations · Cited by this paper
  37. Prospective Study of Body Mass Index, Weight Change, and Risk of Adult-onset Asthma in Women · Carlos A. Camargo · 1999 · 859 citations · Cited by this paper
  38. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments · Giovanni Targher · 2021 · 855 citations · Cited by this paper
  39. Rising rural body-mass index is the main driver of the global obesity epidemic in adults · Honor Bixby · 2019 · 757 citations · Cited by this paper

Source: OpenAlex (CC0)